Length of hospital stay · patients with promoting growth and neurodevelopment in stable preterm twins
1 finding from 1 review
no estimate extracted
1 study · 6 participants
Very low
Duration of sick‐leave Sick‐leave > 21 days · participants with acute or subacute low‐back pain
It is very uncertain whether back school changes duration of sick‐leave Sick‐leave > 21 days compared with combined physical therapies (very low certainty).
1 finding from 1 review
Work absence · participants with acute or subacute low‐back pain
It is very uncertain whether back school + other treatment changes work absence at 30 days Number of participants on sick‐leave compared with other treatment alone (very low certainty).
1 finding from 1 review
Days of sick‐leave at 1 year · participants with acute or subacute low‐back pain
1 finding from 1 review
Duration of sick‐leave Sick‐leave > 21 days · participants with acute or subacute low‐back pain
It is very uncertain whether back school changes duration of sick‐leave Sick‐leave > 21 days compared with short‐wave diathermy at the lowest intensity (very low certainty).
1 finding from 1 review
Duration of total antimicrobial treatment · children with cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Duration of intravenous antimicrobial treatment · children with cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Duration of oral antimicrobial treatment · children with cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Length of hospital stay · adults undergoing elective surgery under general anaesthesia
1 finding from 1 review
Clinical remission or improvement · patients with Induction of remission or response in Crohn's disease
It is very uncertain whether mesalamine changes induction of remission (CDAI < 150) or clinical improvement ‐… compared with sulfasalazine (alone or (very low certainty).
2 findings from 1 review
Disease‐free period at 30, 60 and 90 days · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
Cardiac mortality · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Disease‐free period at 30, 60 and 90 days · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Cardiac mortality · chronic heart failure in Chagas cardiomyopathy patients
1 finding from 1 review
30‐Day mortality · Patients undergoing thoracotomy
Paravertebral blockade showed no clear difference in 30‐day mortality compared with thoracic epidural blockade (low certainty).
1 finding from 1 review
Healthy days · people with people with serious mental illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospitalisation and institutionalisation (days) · malnourished or nutritionally at‐risk adults
1 finding from 1 review
Intervention not reported
Health behaviour: return tuberculin test rate, 3 days Unidirectional ATCS versus no calls · patients/healthcare consumers
1 finding from 1 review
Intervention not reported
Behavioural outcomes: number of drinks per drinking day ATCS Plus, IVR versus usual care, (various) controls at median · participants addicted to alcohol
1 finding from 1 review
Intervention not reported
Behavioural outcomes: drinking days, heavy drinking days, or total number of drinks consumed ATCS Plus, IVR versus (various) controls · participants addicted to alcohol
1 finding from 1 review